Wave Life Sciences Ltd. (Nasdaq: WVE) announced positive interim data from the Phase 1 portion of its first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA, in otherwise healthy individuals living with overweight or obesity. The trial results showed significant placebo-adjusted reductions in visceral fat by 14% (p<0.05) and total fat by 5%, alongside stabilization of lean mass and reductions in waist circumference and body weight. These findings suggest that WVE-007 may offer a promising therapeutic option for individuals struggling with obesity, particularly in preserving muscle while promoting fat loss.

The data indicates that a single 240 mg dose of WVE-007 led to clinically meaningful improvements in body composition at the six-month follow-up. Notably, the trial participants had a lower average BMI compared to those in later-stage obesity studies, which may enhance the potential for further improvements in the upcoming Phase 2a trial. Wave Life Sciences plans to initiate this next phase in the second quarter of 2026, targeting individuals with higher BMI and comorbidities.

The company also highlighted that WVE-007 continues to be generally safe and well-tolerated, with no severe treatment-emergent adverse events reported. The management team will host an investor conference call to discuss these results in detail, further emphasizing the company's commitment to advancing its innovative RNA medicines platform. The positive interim results are expected to bolster investor confidence and potentially enhance the company's market position in the competitive obesity treatment landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.